XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared
with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).